Ligand-Based Pharmacophore Modelling Targeting α-Synuclein Misfolding for an Effective Treatment of Parkinson’s Disease
Keywords:
In silico ADMET, Ligand-based drug design, Natural products, Parkinson’s disease, Pharmacophore model, α-synuclein inhibitors.Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disease prominently observed in elderly population. Aggregation and misfolding of α-synuclein protein is strongly implicated as an underlying pathogenesis of the disease. PD is characterised by high amount of intracellular α-synuclein as the main constituents in Lewy bodies. However, PD drugs in clinical conditions elicit unpleasant side effects and develop resistance after long time application, making a search for better candidates imperative. This study is aimed at identifying potent inhibitors of α-synuclein from interbioscreen (IBS) database using ligand-based pharmacophore modelling, Glide standard precision docking, molecular dynamics, and pk-CSM pharmacokinetics parameters. Among the ten models generated, only one of the pharmacophore models was validated with Guner-Henry’s goodness of hits (GH) scoring method and enrichment factor (EF) of 0.87 and 23.43 respectively, making it ideal for database screening. The pharmacophore model with features, HHHHHHDDDDA identified 100 hits from “877,337” IBS database natural compounds. The top hits, STOCK2S-85121, STOCK3S-13122, STOCK2S-57139, STOCK7S-07150, and STOCK4S-24924 demonstrated better docking scores of -4.789, -4.451, -4.413, -4.365 and -4.227 kcal/mol respectively, while the standard, Levodopa has docking score of -3.556 kcal/mol. The retrieved compounds have similar amino acid interactions with the standard compound (levodopa). The ligands are predicted to have good Blood Brain Barrier permeation, central nervous system penetrations and absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties. Molecular dynamics for 50 ns further suggested that the highest docked compound (STOCK2S-85121) was stable into the binding pocket and displayed strong hydrogen bond interactions. Therefore, the compound is recommended for further evaluations as potential anti-PD agents.References
A. Kouli, K. M. Torsney and W. L. Kuan, Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Brisbane (AU): Codon Publications, 2018.
H. Liu, L. Chen, F. Zhou, Y. -X. Zhang, J. Xu, M. Xu, et al. Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation, Bioorganic & Medicinal Chemistry, 27(14), 2019, 3089-3096.
H. Liu, L. Chen, F. Zhou, Y. -X. Zhang, J. Xu, M. Xu, et al. Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation, Bioorganic & Medicinal Chemistry, 27(14), 2019, 3089-3096.
E. Mariani, M. C. Polidori, A. Cherubini and P. Mecocci, Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview, Journal of Chromatography B, Analytical Technologies in the Bimedical and Life Sciences, 827(1), 2015, 65-75.
M. T. Ardah, K. E. Paleologou, G. Lv, S. B. Abul Khair, A. S. Kazim, S. T. Minhas, et al., Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity, Frontiers in Aging Neuroscience, 6, 2014, 197.
F. E. Herrera, A. Chesi, K. E. Paleologou, A. Schmid, A. Munoz, M. Vendruscolo, et al., Inhibition of α-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region, PLoS One, 3(10), 2008, e3394.
L. Breydo, J. W. Wu and V. N. Uversky, α-Synuclein misfolding and parkinson's disease, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1822(2), 2012, 261-285.
L. Yu, J. Cui, P. K. Padakanti, L. Engel, D. P. Bagchi, P. T. Kotzbauer, et al., Synthesis and in vitro evaluation of α-synuclein ligands, Bioorganic & Medicinal Chemistry, 20(15), 2012, 4625-4634.
N. Török, Z. Majláth, L. Szalárdy and L. Vécsei, Investigational α-synuclein aggregation inhibitors: hope for Parkinson’s disease, Expert Opinion on Investigational Drugs, 25(11), 2016, 1281-1294.
I. Zahoor, A. Shafi and E. Haq, Pharmacological treatment of Parkinson’s disease, Exon Publications, 2018, 129-44.
S. S. Jafaripour, S. Gharaghani, E. Nazarshodeh, S. Haider and A. A. Saboury, In silico drug repositioning of FDA-approved drugs to predict new inhibitors for alpha-synuclein aggregation, Computational Biology and Chemistry, 88, 2020, 107308.
R. Kumar, R. Bavi, M. G. Jo, V. Arulalapperumal, A. Baek and S. Rampogu, et al., New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro, Scientific Reports, 7(1), 2017, 1-14.
J. H. Lu, M. T. Ardah, S. S. K. Durairajan, L. F. Liu, L. X. Xie, W. F. D. Fong, et al., Baicalein inhibits formation of α‐synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation, Chembiochem, 12(4), 2011, 615-624.
K. K. Sahu, M. T. Woodside and J. A. Tuszynski, α-synuclein dimer structures found from computational simulations, Biochimie, 116, 2015, 133-140.
S. Kamzolova, V. Sivozhelezov, A. Sorokin, T. Dzhelyadin, N. Ivanova and R. Polozov, RNA polymerase-promoter recognition. Specific features of electrostatic potential of “early” T4 phage DNA promoters, Journal of Biomolecular Structure and Dynamics, 18(3), 2000, 325-334.
C. Charlier, G. Bouvignies, P. Pelupessy, A. Walrant, R. Marquant, M. Kozlov, et al., Structure and dynamics of an intrinsically disordered protein region that partially folds upon binding by chemical-exchange NMR, Journal of the American Chemical Society, 139(35), 2017, 12219-12227.
V. Prachayasittikul, A. Worachartcheewan, W. Shoombuatong, N. Songtawee, S. Simeon, V. Prachayasittikul, et al., Computer-aided drug design of bioactive natural products, Current Topics in Medicinal Chemistry, 15(18), 2015, 1780-1800.
M. Masuda, N. Suzuki, S. Taniguchi, T. Oikawa, T. Nonaka, T. Iwatsubo, et al., Small molecule inhibitors of α-synuclein filament assembly, Biochemistry, 45(19), 2006, 6085-6094.
M. G. Tigan, A. Ghahghaei and M. Lagzian, In-vitro and in-silico investigation of protective mechanisms of crocin against E46K α-synuclein amyloid formation, Molecular Biology Reports, 46(4), 2019, 4279-4292.
Y. Zhao, F. Ye, J. Xu, Q. Liao, L. Chen, W. Zhang, et al., Design, synthesis and evaluation of novel bivalent β-carboline derivatives as multifunctional agents for the treatment of Alzheimer's disease, Bioorganic & Medicinal Chemistry, 26(13), 2018, 3812-3824.
G. Wolber and T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, Journal of Chemical Information and Modeling, 45(1), 2005, 160-169.
G. Marcou and A. Varnek, Relational chemical databases: creation, management, and usage, Tutorials in Chemoinformatics, 2017, 37-66.
C. M. Adrià, S. Garcia-Vallvé and G. Pujadas, DecoyFinder, a tool for finding decoy molecules, Journal of Cheminformatics, 4(1), 2012.
L. Wang, X. Pang, Y. Li, Z. Zhang and W. Tan, RADER: a RApid DEcoy Retriever to facilitate decoy based assessment of virtual screening, Bioinformatics, 33(8), 2017, 1235-1237.
R. Pascual, C. Almansa, C. Plata-Salamán and J. M. Vela, A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset, Frontiers in Pharmacology, 10(519), 2019.
I. Wallach and R. Lilien, Virtual decoy sets for molecular docking benchmarks, Journal of Chemical Information and Modeling, 51(2), 2011, 196-202.
M. M. Niu, J. Y. Qin, C. P. Tian, X. H. Yan, F. G. Dong, Z. Q. Cheng, et al., Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking, Acta Pharmacologica Sinica, 35(7), 2014, 967-979.
V. Temml, U. Garscha, E. Romp, G. Schubert, J. Gerstmeier, Z. Kutil, et al., Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening, Scientific Reports, 7(1), 2017, 1-8.
D. E. Pires, T. L. Blundell and D. B. Ascher, pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, Journal of Medicinal Chemistry, 58(9), 2015, 4066-4072.
T. S. Ulmer, A. Bax, N. B. Cole and R. L. Nussbaum, Structure and dynamics of micelle-bound human α-synuclein, Journal of Biological Chemistry, 280(10), 2005, 9595-9603.
R. L. Jayaraj and N. Elangovan, In silico identification of potent inhibitors of alpha-synuclein aggregation and its in vivo evaluation using MPTP induced Parkinson mice model, Biomedicine & Aging Pathology, 4(2), 2014, 147-152.
R. L. Jayaraj, V. Ranjani, K. Manigandan and N. Elangovan, In silico docking studies to identify potent inhibitors of alpha-synuclein aggregation in Parkinson disease, Asian Journal of Pharmaceutical and Clinical Research, 6(4), 2013, 127-131.
K. Jenkins, T. Mateeva, I. Szabó, A. Melnik, P. Picotti, A. Csikász-Nagy, et al., Combining data integration and molecular dynamics for target identification in α-Synuclein-aggregating neurodegenerative diseases: Structural insights on Synaptojanin-1 (Synj1), Computational and Structural Biotechnology Journal, 18, 2020, 1032-1042.
T. Mohankumar, V. Chandramohan, H. S. Lalithamba, R. L. Jayaraj, P. Kumaradhas, M. Sivanandam, et al., Design and molecular dynamic investigations of 7, 8-dihydroxyflavone derivatives as potential neuroprotective agents against alpha-synuclein, Scientific Reports, 10(1), 2020, 1-10.
I. Ahmad, H. Jadhav, Y. Shinde, V. Jagtap, R. Girase and H. Patel, Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors, In Silico Pharmacology, 9(1), 2021, 23.
W. L. Jorgensen, D. S. Maxwell, J. Tirado-Rives, Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids, Journal of the American Chemical Society, 118(45), 1996, 11225-11236.
H. M. Patel, I. Ahmad, R. Pawara, M. Shaikh and S. Surana, In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation, Journal of Biomolecular Structure & Dynamics, 39(4), 2021, 1491-1505.
G. Kalibaeva, M. Ferrario and G. Ciccotti, Constant pressure-constant temperature molecular dynamics: a correct constrained NPT ensemble using the molecular virial, Molecular Physics, 101(6), 2003, 765-778.
M. C. Gidaro, S. Alcaro, D. Secci, D. Rivanera, A. Mollica, M. Agamennone, et al., Identification of new anti-Candida compounds by ligand-based pharmacophore virtual screening, Journal of Enzyme Inhibition and Medicinal Chemistry, 31(6), 2016, 1703-1706.
A. Vuorinen, R. Engeli, A. Meyer, F. Bachmann, U. J. Griesser, D. Schuster, et al., Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors, Journal of Medicinal Chemistry, 57(14), 2014, 5995-6007.
T. Sindhu, T. Venkatesan, G. R. Gracy, S. K. Jalali and A. Rai, Exploring the resistance-developing mutations on Ryanodine receptor in diamondback moth and binding mechanism of its activators using computational study, Biochemical Engineering Journal, 121, 2017, 59-72.
D. E. Pires, T. L. Blundell and D. B. Ascher, pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, Journal of Medicinal Chemistry, 58(9), 2015, 4066-4072.
O. M. El-Agnaf, K. E. Paleologou, B. Greer, A. M. Abogrein, J. E. King, S. A. Salem, et al., A strategy for designing inhibitors of α‐synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders, The FASEB Journal, 18(11), 2004, 1315-1317.
N. D. Gajjar, T. M. Dhameliya and G. B. Shah, In search of RdRp and Mpro inhibitors against SARS CoV-2: Molecular docking, molecular dynamic simulations and ADMET analysis, Journal of Molecular Structure, 1239, 2021, 130488.
S. John, S. Thangapandian, S. Sakkiah and K. W. Lee, Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies, BMC Bioinformatics, 12 (Suppl 1), 2011, S28.
R. Kumar, R. Bavi, M. G. Jo, V. Arulalapperumal, A. Baek, S. Rampogu, et al., New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro, Scientific Reports, 7(1), 2017, 10827.
C. Suenderhauf, F. Hammann and J. Huwyler, Computational prediction of blood-brain barrier permeability using decision tree induction, Molecules, 17(9), 2012, 10429-10445.
U. Norinder and M. Haeberlein, Computational approaches to the prediction of the blood–brain distribution, Advanced Drug Delivery Reviews, 54(3), 2002, 291-313.
L. Ioakimidis, L. Thoukydidis, A. Mirza, S. Naeem and J. Reynisson, Benchmarking the reliability of QikProp. correlation between experimental and predicted values, QSAR & Combinatorial Science, 27(4), 2008, 445-456.
A. Castro-Alvarez, A. M. Costa and J. Vilarrasa, The performance of several docking programs at reproducing protein-macrolide-like crystal structures, Molecules, 22(1), 2017.
D. Ramirez and J. Caballero, Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data?, Molecules, 23(5), 2018.
M. Deffains, M. H. Canron, M. Teil, Q. Li, B. Dehay, E. Bezard, et al., L-DOPA regulates α-synuclein accumulation in experimental parkinsonism, Neuropathology and Applied Neurobiology, 47(4), 2021, 532-543.
J. Joubert, Bicyclic bis-heteroaryl derivatives as inhibitors of the α-synuclein protein: a patent evaluation of WO2018138088A1, Expert Opinion on Therapeutic Patents, 28(12), 2018, 939-945.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:Authors hold and retain copyright, and grant the journal right of first publication, with the work after publication simultaneously licensed under a Creative Commons Attribution 4.0 License CC BY that permits any use, reproduction and distribution of the work and article without further permission provided that the original work is properly cited.
Authors are permitted and encouraged to post their work online in institutional repositories, website and other social media before and after publication, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
